STOCK TITAN

Neurogene (NGNE) Chief Commercial Officer listed in new Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Neurogene Inc. submitted an initial insider ownership report on Form 3 for Christina Shafer, who serves as the company’s Chief Commercial Officer. The filing does not list any equity transactions or derivative positions, and the transaction summary shows zero buy, sell, or exercise activity.

Positive

  • None.

Negative

  • None.
Form 3 regulatory
"INSIDER FILING DATA (Form 3):"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Chief Commercial Officer financial
""officer_title": "Chief Commercial Officer""
A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.
transactionSummary financial
""transactionSummary": {"
derivativeSummary financial
""derivativeSummary": [],"
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Shafer Christina

(Last)(First)(Middle)
535 W 24TH STREET, 5TH FLOOR

(Street)
NEW YORK NEW YORK 10011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2026
3. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
No securities are beneficially owned.
Donna M. Cochener, Attorney-in-Fact for Christina Shafer04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Neurogene (NGNE) disclose about Christina Shafer in this Form 3?

The filing identifies Christina Shafer as an officer of Neurogene Inc., serving as Chief Commercial Officer. It is an initial insider ownership report and, in this case, does not show any equity transactions or derivative holdings for her within the reported data fields.

Does the Neurogene (NGNE) Form 3 for Christina Shafer show any stock transactions?

No, the Form 3 data for Neurogene Inc.’s Chief Commercial Officer shows zero buy, sell, or exercise transactions. The transactionSummary fields report no shares bought, sold, exercised, gifted, or withheld for taxes during the period covered by this initial report.

Are any derivative securities reported for Christina Shafer in Neurogene (NGNE)’s Form 3?

The Form 3 lists an empty derivativeSummary, indicating no derivative positions such as options or similar instruments are reported for Christina Shafer. All derivative-related transaction counts and share amounts in the transactionSummary are zero in this filing’s structured data.

What does the transactionSummary indicate in Neurogene (NGNE)’s Form 3 filing?

The transactionSummary indicates there were no insider equity activities for Christina Shafer. BuyCount, sellCount, exerciseCount, giftCount, and taxWithholdingCount are all zero, and netBuySellDirection is listed as neutral, reflecting the absence of reported share movements in this Form 3.

What insider role is confirmed for Christina Shafer at Neurogene (NGNE) in this filing?

The filing confirms that Christina Shafer is an officer of Neurogene Inc. with the title Chief Commercial Officer. She is not identified as a director or ten percent owner in the provided data fields associated with this Form 3 submission.